Zogenix Inc. has struck a deal to buy Modis Therapeutics Inc. for $250m upfront, giving it control of another late-phase rare disease drug to complement its lead product, Fintepla.
Zogenix To Pay $250m Upfront To Buy Modis For Ultra-Orphan Drug
The takeover will diversify Zogenix’s pipeline through the addition of MT1621, a drug that improved the probability of survival in patients with an inherited mitochondrial DNA depletion disorder.
